The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China

References

• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342–350.
   PubMed Web of Science ®Google Scholar
• De la Fuente J, Baruchel A, Biondi A, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33–47.
   PubMed Web of Science ®Google Scholar
• Millot F, Traore P, Guilhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116: 140–143.
   PubMed Web of Science ®Google Scholar
• Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119:1821–1830.
   PubMed Web of Science ®Google Scholar
• Hasan SK, Sazawal S, Kumar B, et al. Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genet Cytogenet. 2006;169:76–77.
   PubMedGoogle Scholar
• Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN practical guidelines in oncology (NCCN Guidelines) 2017 [Internet]. [cited 2017 Oct 19]. Available from: https://www.nccn.org/patients/guidelines/cml/index.html.
   Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758–3765.
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232–238.
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096–2102.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121:4867–4874.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353–1360.
   PubMed Web of Science ®Google Scholar
• Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30: 4323–4329.
   PubMed Web of Science ®Google Scholar
• Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120:291–294.
   PubMed Web of Science ®Google Scholar
• Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660.
   PubMed Web of Science ®Google Scholar
• Yue Y, Gui X, He X, et al. Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 > 10% at 3 months who are early switched to nilotinib. Hematology. 2016;21:213–217.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122: 872–884.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27:2016–2022.
   PubMed Web of Science ®Google Scholar
• Sokal J, Baccarani M, Tura S, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985;66:1352–1357.
   PubMed Web of Science ®Google Scholar
• Gurrea Salas D, Glauche I, Tauer JT, et al. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol. 2015;94:1363–1371.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Hochhaus A, Lauseker M, et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25:1433–1438.
   PubMed Web of Science ®Google Scholar
• Muller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957–1963.
   PubMed Web of Science ®Google Scholar
• Millot F, Guilhot J, Baruchel A, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014;124:2408–2410.
   PubMedGoogle Scholar
• Giona F, Saglio G, Santopietro M, et al. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. Br J Haematol. 2016 [Dec 16]. doi: 10.1111/bjh.14458
   Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93:71–80.
   PubMed Web of Science ®Google Scholar